Simultaneous HPLC determination of metronidazole and spiramycin in plasma and brain of mouse

Current Pharmaceutical Analysis

Volumn 7, Issue 4, 2011, Pages 262-267

  Kit, Chew W ^a   Segarra, Ignacio ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Brain uptake; Drug drug interaction; Metronidazole; Spiramycin; Toxoplasma gondii

Indexed keywords

METRONIDAZOLE; SPIRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG UPTAKE; LIMIT OF QUANTITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

MURINAE; MUS; TOXOPLASMA GONDII;

EID: 80053477464     PISSN: 15734129     EISSN: 1875676X     Source Type: Journal    
DOI: 10.2174/157341211797458032     Document Type: Article

References (39)

1. Montoya, J.G.; Liesenfeld, O. Toxoplasmosis. Lancet, 2004, 363, 1965-1976.
2. Daryani, A.; Sharif, M.; Hosseini, S.H.; Karimi, S.A.; Gholami, S. Serological survey of Toxoplasma gondii in schizophrenia patients referred to psychiatric hospital, Sari city, Iran. Trop. Biomed., 2010, 27, 476-486.
3. Webster, J.P.; Lamberton, P.H.L.; Donnelly, C.A.; Torrey, E.F. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc. Bio. Sci. 2006, 273, 1023-1030.
4. Luft, B.J.; Remington, J.S. Toxoplasmic encephalitis in AIDS. Clin. Inf. Dis., 1992, 15, 211-222.
5. Porter, S.B.; Sande, M. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N. Eng. J. Med., 1992, 327, 1643-1648.
6. Araujo, F.G.; Shepard, R.M.; Remington J.S. In vivo activity of macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur. J. Clin. Microbiol. Inf. Dis., 1991, 10, 519-524.
7. Israelski, D.M.; Remington, J.S. Toxoplasmosis in the non-AIDS immunocompromised host. Cur. Clin. Top. Inf. Dis., 1993, 13, 322-356.
8. Djurković-Djaković, O.; Nikolić, T.; Robert-Gangneux, F.; Bobić, B.; Nikolić, A. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrob. Agents Chemother., 1999, 43, 2240-2244.
9. Cook, A.J.; Gilbert, R.E.; Buffolano, W.; Zufferey, J.; Petersen, E.; Dunn, D.T. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. Br. Med. J., 2000, 321, 142-147.
10. Schoondermark-Van de Ven, E.; Melchers, W.; Camps, W.; Eskes, T.; Meuwissen, J.; Galama, J. Effectiveness of spiramycin for treatment of congenital Toxoplasma gondii infection in rhesus monkeys. Antimicrob. Agents Chemother., 1994, 38, 1930-1936.
11. Grujić, J.; Djurković-Djaković, O.; Nikolić, A.; Klun, I.; Bobić, B. Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis. Int. J. Antimicrob. Agents, 2004, 25, 226-230.
12. Meroni, V.; Genco, F.; Tinelli, C.; Lanzarini, P.; Bollani, L.; Stronati, M.; Petersen, E. Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies. Clin. Vac. Immunol., 2009, 16, 1517-1520.
13. Tian, X.; Li, J.; Zamek-Gliszczynski, M.J.; Bridges, A.S.; Zhang, P.; Patel, N.J.; Raub, T.J.; Pollack, G.M.; Brouwer, K.L. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother., 2007, 51, 3230-3234.
14. Shia, X.G.; Fawcettb, J.P.; Chena, X.Y.; Zhonga, D.F. Structural identification of bitespiramycin metabolites in rat: a single oral dose study. Xenobiotica, 2005, 35, 343-358.
15. Frydman, A.M.; Le Roux, Y.; Desnottes, J.F.; Kaplan, P.; Djebbar, F.; Cournot, A.; Duchier, J.; Gaillot, J. Pharmacokinetics of spiramycin in man. J. Antimicrob. Chemother., 1998, 22, 93-103.
16. Cudmore, S.L.; Delgaty, K.L.; Hayward-McClelland, S.F.; Petrin, D.P.; Garber, G.E. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin. Microbiol. Rev., 2004, 17, 783-793.
17. Bruton, L.L.; Parker, K.L.; Blumenthal, D.; Buxton, I. In: Goodman and Gilman's Manual of Pharmacology and Therapeutics; I. Buxon, Ed.; McGraw-Hill: New York, 2008; pp. 687-688.
18. Lacy, C.F.; Armstrong, L.L.; Goldman, M.P.; Lance L.L. In: Lexi- Comp's Drug Information Handbook; L.L. Lance, Ed.; Lexi-Comp: Hudson, USA, 2006; pp. 1124-1126.
19. Schwartz, D.E.; Jeunet, F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemother., 1976, 22, 19-29.
20. Jokipii, A.M.M.; Myllyla, V.V.; Hokkanen, E.; Jokipii, L. Penetration of the blood brain barrier by metronidazole and tinidazole. J. Antimicrob. Chemother., 1977, 3, 239-245.
21. Jensen, J.C.; Gugler, R. Single- and multiple-dose metronidazole kinetics. Clin. Pharmacol. Ther., 1993, 34, 481-487.
22. Emami, J.; Ghassami, N.; Hamishehkar, H. A rapid and sensitive HPLC method for the analysis of metronidazole in human plasma: application to single dose pharmacokinetic and bioequivalence studies. DARU, 2006, 14, 15-21.
23. Silva, M.; Fawcett, J.P.; Chena, X.Y.; Zhonga, D.F. Development and validation of a HPLC-MS-MS method for quantification of metronidazole in human plasma. J. Chromatogr. Sci., 2009, 47, 781-784.
24. Chepkwony, H.K.; Vermaelen, A.; Roets, E.; Hoogmartens, J. Development and validation of a reversed-phase liquid chromatography method for analysis of spiramycin and related substances. Chromatographia, 2001, 54, 51-56.
25. Khattab, F.I.; Ramadan, N.K.; Hegazy, M.A.; Ghoniem, N.S. Simultaneous determination of metronidazole and spiramycin in bulk powder and in tablets using different spectrophotometric techniques. Drug Test Anal., 2010, 2, 37-44.
26. Maher, H.M.; Youssef, R.M.; Khalil, R.H.; El-Bahr, S.M. Simultaneous multiresidue determination of metronidazole and spiramycin in fish muscle using high performance liquid chromatography with UV detection. J. Chromatogr. B, 2008, 876, 175-181.
27. Sagan, C.; Salvador, A.; Dubreuil, D.; Poulet, P.P.; Duffaut, D.; Brumpt, I. Simultaneous determination of metronidazole and spiramycin I in human plasma, saliva and gingival crevicular fluid by LC-MS/MS. J. Pharm. Biomed. Anal., 2005, 38, 298-306.
28. Rotzetter, P.A.; Le Libous, A., Pichard, E.; Cimasoni, G. Kinetics of spiramycin/metronidazole (Rodogyl) in humna gingival crevicular fluid, saliva and blood. J. Clin. Periodontol., 1994, 21, 595-600.
29. Poulet, P.P.; Duffaut, D.; Barthet, P.; Brumpt, I. Concentrations and in vivo antibacterial activity of spiramycin and metronidazole in patients with periodontitis treated with high-dose metronidazole and the spiramycin/metronidazole combination. J. Antimicrob. Chemother., 2005, 55, 347-351.
30. Pennisi, M.G.; De Majo, M.; Masucci, M.; Britti, D.; Vitale, F.; Del Maso, R. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet. Rec., 2005, 156, 346-349.
31. Everett, E.D. Metronidazole and amoebiasis. Am. J. Dig. Dis., 1974, 19, 626-636.
32. Mack, D.G.; McLeod, R. New micromethod to study the effect of anti-microbial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole and cyclosporine A. Antimicrob. Agents Chemother., 1984, 26, 26-30.
33. Tan, S.Y.; Kan, E.; Lim, W.Y.; Chay, G.; Law, J.H.K.; Soo, G.W.; Bukhari, N.I.; I. Segarra. Metronidazole leads to enhanced uptakeof imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. J. Pharm. Pharmacol., 2011, 63, 918-925.
34. Dilger, K.; Fux, R.; Röck, D.; Mörike, K.; Gleiter, C.H. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study. J. Clin. Pharmacol., 2007, 47, 1532-1539.
35. Roedler, R.; Neuhauser, M.M.; Penzak, S.R. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann. Pharmacother., 2007, 41, 653-658.
36. Saito, H.; Fukasawa, Y.; Otsubo, Y.; Yamada, K.; Sezaki, H.; Yamashita, S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm. Res., 2000, 17, 761-765.
37. Berstad, A.; Berstad, K.; Wilhelmsen, I.; Hatlebakk, J.G.; Nesje, L.B.; Hausken, T. Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. Aliment. Pharmacol. Ther., 1995, 9, 197-200.
38. Kim, K.A.; Park, J.Y. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur. J. Clin. Pharmacol., 2010, 66, 721-725.
39. Wang, J.S.; Backman, J.T.; Kivistö, K.T.; Neuvonen, P.J. Effects of metronidazole on midazolam metabolism in vitro and in vivo. Eur. J. Clin. Pharmacol., 2000, 56, 555-559.